← Eichor
Condition: Kras Nras Hras Mutated Nsclc Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Kras Nras Hras Mutated Nsclc

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Phase 1/Phase 2 · 6 location(s) · Revolution Medicines, Inc. · NCT07397338Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Phase 1/Phase 2 · 93 location(s) · Revolution Medicines, Inc. · NCT06162221Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Phase 3 · 152 location(s) · Revolution Medicines, Inc. · NCT06881784
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.